EUVIMEDEUVIMED entdecken
Crossref

Thiazolidinones as Potential PGK1 Inhibitors for Treatment of Osteosarcoma Growth and Metastasis

Xuwen Chen, Meng Li, Zongjing Hu, Donghui Sun, Yikai Xu, Wenwen Dong, Tong Zhu, Weibin Zhang, Shunying Liu iD

Journal of Medicinal Chemistry · 13.11.2025 · 68 (21) · 22216-22245

DOI: 10.1021/acs.jmedchem.5c00738 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 17.10.2025. Verfasst von Xuwen Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China No…. Hauptthemen laut MEDLINE: Osteosarcoma, Phosphoglycerate Kinase, Thiazolidines, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteosarcoma is one of the malignant bone tumors in children and adolescents. Due to unclear pathogenesis and lack of identified drug targets, there has been limited progress in developing targeted therapies in the past 50 years. Here, we conducted an extensive structure–activity relationship study of thiazolidinone inhibitors by phenotypic screening to discover compound 60, which demonstrates potent cellular activity in MNNG-HOS cells (IC50 = 0.072 μM) and exhibits significant antitumor effect (61.6% inhibition of OS growth in vivo) and low toxicity. Compound 60 also shows a good pharmacokinetic profile with a bioavailability F = 80% following intraperitoneal administration. The photo-cross-linking probes were designed and synthesized from 60 to identify PGK1 as a potential target of 60 using an activity-based protein profiling strategy. Western blot, shRNA knockdown, wound healing assays, cellular thermal shift assays, cell colony formation, and transwell assays suggest that 60 is a promising PGK1 inhibitor for OS treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaPhosphoglycerate KinaseThiazolidinesAntineoplastic AgentsBone NeoplasmsProtein Kinase InhibitorsHumansAnimalsStructure-Activity RelationshipCell ProliferationCell Line, TumorMiceMice, Nude

Substanzen

Phosphoglycerate KinaseThiazolidinesPGK1 protein, humanAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China.
  • Department of Orthopaedics, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.

ORCID-Profile: Shunying Liu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Chen, X., Li, M., Hu, Z., Sun, D., Xu, Y., Dong, W., Zhu, T., Zhang, W., & Liu, S. (2025). Thiazolidinones as Potential PGK1 Inhibitors for Treatment of Osteosarcoma Growth and Metastasis. Journal of Medicinal Chemistry, 68(21), 22216-22245. https://doi.org/10.1021/acs.jmedchem.5c00738

Vancouver

Chen X, Li M, Hu Z, Sun D, Xu Y, Dong W, et al. Thiazolidinones as Potential PGK1 Inhibitors for Treatment of Osteosarcoma Growth and Metastasis. Journal of Medicinal Chemistry. 2025;68(21):22216-22245. doi:10.1021/acs.jmedchem.5c00738

BibTeX
@article{Chen2025,
  author = {Chen, Xuwen and Li, Meng and Hu, Zongjing and Sun, Donghui and Xu, Yikai and Dong, Wenwen and Zhu, Tong and Zhang, Weibin and Liu, Shunying},
  title = {Thiazolidinones as Potential PGK1 Inhibitors for Treatment of Osteosarcoma Growth and Metastasis},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {21},
  pages = {22216--22245},
  doi = {10.1021/acs.jmedchem.5c00738}
}
Kostenlos starten →